Brian Jonas

Title(s)Professor, MED: Int Med HMCTBMT
SchoolSchool of Medicine
AddressCancer Ctr So, #3016
CA 95817
Phone916-734-3772
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. This differentiation block will not stand, man: ivosidenib for MDS. Blood Adv. 2024 Aug 13; 8(15):4207-4208. Beechinor RJ, Jonas BA. PMID: 39136969.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood. 2024 Aug 12. Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA. PMID: 39133921.
      View in: PubMed   Mentions:    Fields:    
    3. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). Leuk Lymphoma. 2024 Aug; 65(8):1145-1152. Cortes J, Jonas BA, Schiller G, Mims A, Roboz GJ, Wei AH, Montesinos P, Ferrell PB, Yee KW, Fenaux P, Schwarer A, Watts JM. PMID: 38538632.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy? Blood Rev. 2024 May; 65:101184. Uy GL, DeAngelo DJ, Lozier JN, Fisher DM, Jonas BA, Magnani JL, Becker PS, Lazarus HM, Winkler IG. PMID: 38493006; PMCID: PMC11051645.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    5. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 04; 99(4):615-624. Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, Turgut M, Ku G, Miller C, Zhou Y, Zhang M, Chyla B, Potluri J, DiNardo CD. PMID: 38343151.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    6. Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial. Clin Lymphoma Myeloma Leuk. 2024 Jun; 24(6):364-374. Konopleva MY, Dail M, Daver NG, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Dunshee DR, Hamidi H, Ott MG, Hong WJ, Andreeff M. PMID: 38378362.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    7. Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77. Gaut D, Oliai C, Boiarsky J, Zhang S, Salhotra A, Azenkot T, Kennedy VE, Khanna V, Olmedo Gutierrez K, Shukla N, Moskoff B, Park G, Afkhami M, Patel A, Jeyakumar D, Mannis G, Logan AC, Jonas BA, Schiller G. PMID: 37801340.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts. Lancet Haematol. 2023 Sep; 10(9):e767-e776. Shallis RM, Daver N, Altman JK, Komrokji RS, Pollyea DA, Badar T, Bewersdorf JP, Bhatt VR, de Botton S, de la Fuente Burguera A, Carraway HE, Desai P, Dillon R, Duployez N, El Chaer F, Fathi AT, Freeman SD, Gojo I, Grunwald MR, Jonas BA, Konopleva M, Lin TL, Mannis GN, Mascarenhas J, Michaelis LC, Mims AS, Montesinos P, Pozdnyakova O, Pratz KW, Schuh AC, Sekeres MA, Smith CC, Stahl M, Subklewe M, Uy GL, Voso MT, Walter RB, Wang ES, Zeidner JF, Žucenka A, Zeidan AM. PMID: 37572683.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Adv. 2023 07 11; 7(13):3117-3127. de Botton S, Fenaux P, Yee K, Récher C, Wei AH, Montesinos P, Taussig DC, Pigneux A, Braun T, Curti A, Grove C, Jonas BA, Khwaja A, Legrand O, Peterlin P, Arnan M, Blum W, Cilloni D, Hiwase DK, Jurcic JG, Krauter J, Thomas X, Watts JM, Yang J, Polyanskaya O, Brevard J, Sweeney J, Barrett E, Cortes J. PMID: 36724515; PMCID: PMC10362540.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    10. A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML. Leuk Res Rep. 2023; 19:100374. Jonas BA, Potter LA, Galkin M, Tuscano JM. PMID: 37363050; PMCID: PMC10285270.
      View in: PubMed   Mentions: 2  
    11. Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis. Leuk Res. 2023 08; 131:107331. Khanna V, Azenkot T, Liu SQ, Gilbert J, Cheung E, Lau K, Pollyea DA, Traer E, Jonas BA, Zhang TY, Mannis GN. PMID: 37263072.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 05; 21(5):503-513. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. PMID: 37156478.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    13. A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia. Hematol Oncol. 2023 Oct; 41(4):743-752. Jonas BA, Hou JZ, Roboz GJ, Alvares CL, Jeyakumar D, Edwards JR, Erba HP, Kelly RJ, Röllig C, Fiedler W, Brackman D, Siddani SR, Chyla B, Hilger-Rolfe J, Watts JM. PMID: 37086447; PMCID: PMC10757832.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    14. Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. Garcia JS, Flamand Y, Penter L, Keng M, Tomlinson BK, Mendez LM, Koller P, Cullen N, Arihara Y, Pfaff K, Wolff JO, Brunner AM, Galinsky I, Bashey A, Antin JH, Cutler C, Ho V, Jonas BA, Luskin MR, Wadleigh M, Winer ES, Savell A, Leonard R, Robertson T, Davids MS, Streicher H, Rodig SJ, Ritz J, Wu CJ, DeAngelo DJ, Neuberg D, Stone RM, Soiffer RJ. PMID: 36332187; PMCID: PMC10122101.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    15. Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia. Support Care Cancer. 2023 Mar 21; 31(4):224. Pervitsky V, Guglielmo J, Moskoff B, Kneen R, Leija C, Sawicky D, Krackeler ML, Jonas BA, Beechinor R. PMID: 36941508.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    16. Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial. Blood. 2023 03 16; 141(11):1265-1276. Daver NG, Dail M, Garcia JS, Jonas BA, Yee KWL, Kelly KR, Vey N, Assouline S, Roboz GJ, Paolini S, Pollyea DA, Tafuri A, Brandwein JM, Pigneux A, Powell BL, Fenaux P, Olin RL, Visani G, Martinelli G, Onishi M, Wang J, Huang W, Green C, Ott MG, Hong WJ, Konopleva MY, Andreeff M. PMID: 36265087; PMCID: PMC10651777.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    17. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clin Cancer Res. 2022 12 15; 28(24):5272-5279. Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. PMID: 36007102; PMCID: PMC9751752.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    18. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial. Lancet Haematol. 2023 Jan; 10(1):e46-e58. Watts JM, Baer MR, Yang J, Prebet T, Lee S, Schiller GJ, Dinner SN, Pigneux A, Montesinos P, Wang ES, Seiter KP, Wei AH, De Botton S, Arnan M, Donnellan W, Schwarer AP, Récher C, Jonas BA, Ferrell PB, Marzac C, Kelly P, Sweeney J, Forsyth S, Guichard SM, Brevard J, Henrick P, Mohamed H, Cortes JE. PMID: 36370742.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    19. Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. Am J Hematol. 2022 11; 97(11):E422-E425. Jonas BA, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, Konopleva M, Ofran Y, Montesinos P, Kovacsovics T, Jang JH, Kantarjian H, Duan Y, Potluri J, Werner M, Pratz KW. PMID: 36053878; PMCID: PMC10286746.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. Am J Hematol. 2022 11; 97(11):E416-E419. Pratz KW, DiNardo CD, Selleslag D, Li J, Yamamoto K, Konopleva M, Stevens D, Kantarjian H, Traina F, Venditti A, Mayer J, Montez M, Jin H, Duan Y, Brackman D, Zha J, Potluri J, Werner M, Jonas BA. PMID: 36054316.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    21. Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy. Leuk Res. 2022 11; 122:106947. Fisch SC, Tuscano JM, Qi L, Jonas BA. PMID: 36108426.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    22. Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. Cancers (Basel). 2022 Jul 26; 14(15). Azenkot T, Jonas BA. PMID: 35892893; PMCID: PMC9330895.
      View in: PubMed   Mentions: 2  
    23. Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leuk Lymphoma. 2022 11; 63(11):2711-2714. Daver N, Jonas BA, Medeiros BC, Patil U, Yan M. PMID: 35834732.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    24. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML. In Vivo. 2022 Jul-Aug; 36(4):1615-1627. Albert DH, Goodwin NC, Davies AM, Rowe J, Feuer G, Boyiadzis M, Dorritie KA, Mancini M, Gandour-Edwards R, Jonas BA, Borthakur G, Aldoss I, Rizzieri DA, Odenike O, Prebet T, Singh S, Popovic R, Shen YU, McDaniel KF, Kati WM, Modi DA, Motwani M, Wolff JE, Frost DJ. PMID: 35738590; PMCID: PMC9301399.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    25. Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. Am J Hematol. 2022 08; 97(8):E299-E303. Jonas BA, Wei AH, Recher C, DiNardo CD, Jang JH, Pratz K, Panayiotidis P, Montesinos P, Yeh SP, Ivanov V, Fiedler W, Yamauchi T, Duan Y, Mendes W, Potluri J, Tews B, Ofran Y. PMID: 35567776; PMCID: PMC9542845.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    26. Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. Leuk Res. 2022 08; 119:106885. Othman T, Moskoff BN, Ho G, Tenold ME, Azenkot T, Krackeler ML, Fisch SC, Potter LA, Kaesberg PR, Welborn JL, Wun T, Esteghamat NS, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 35738024.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    27. Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. Onco Targets Ther. 2022; 15:423-436. Granowicz EM, Jonas BA. PMID: 35479302; PMCID: PMC9037178.
      View in: PubMed   Mentions: 9  
    28. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood Cancer J. 2022 04 20; 12(4):71. Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, DiNardo CD, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. PMID: 35443742; PMCID: PMC9021259.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    29. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. Am J Hematol. 2022 06 01; 97(6):E191-E194. Kennedy VE, Hui G, Azenkot T, Gaut D, Wieduwilt MJ, Oliai C, Jonas BA, Mittal V, Logan AC, Muffly LS, Mannis GN. PMID: 35266185.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. Blood. 2022 02 24; 139(8):1135-1146. DeAngelo DJ, Jonas BA, Liesveld JL, Bixby DL, Advani AS, Marlton P, Magnani JL, Thackray HM, Feldman EJ, O'Dwyer ME, Becker PS. PMID: 34543383; PMCID: PMC11017789.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    31. NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022. J Natl Compr Canc Netw. 2022 02; 20(2):106-117. Greenberg PL, Stone RM, Al-Kali A, Bennett JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg HJ, DeZern AE, Dinner S, Foucar C, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Jonas BA, Keel S, Madanat Y, Maness LJ, Mangan J, McCurdy S, McMahon C, Patel B, Reddy VV, Sallman DA, Shallis R, Shami PJ, Thota S, Varshavsky-Yanovsky AN, Westervelt P, Hollinger E, Shead DA, Hochstetler C. PMID: 35130502.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    32. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. J Clin Oncol. 2022 03 10; 40(8):855-865. Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. PMID: 34910556; PMCID: PMC8906463.
      View in: PubMed   Mentions: 43     Fields:    Translation:HumansCTClinical Trials
    33. Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leuk Lymphoma. 2022 01; 63(1):231-234. Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM. PMID: 34486920.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Rev Hematol. 2021 05; 14(5):407-417. Othman TA, Tenold ME, Moskoff BN, Azenkot T, Jonas BA. PMID: 34076549; PMCID: PMC8515853.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clin Cancer Res. 2021 09 01; 27(17):4726-4736. Tuscano JM, Poh C, Kaesberg P, Luxardi G, Merleev A, Marusina A, Brunson A, Rosenberg A, Jonas B, Maverakis E. PMID: 34088724; PMCID: PMC9262142.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    36. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. Future Oncol. 2021 Aug; 17(23):2989-3005. Othman TA, Azenkot T, Moskoff BN, Tenold ME, Jonas BA. PMID: 34024158.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    37. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer. 2021 08 15; 127(16):2943-2953. Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, Popovic R, Modi DA, Joshi RH, Wolff JE, Jonas BA. PMID: 33934351; PMCID: PMC8360206.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    38. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Front Oncol. 2021; 11:649209. Tenold ME, Moskoff BN, Benjamin DJ, Hoeg RT, Rosenberg AS, Abedi M, Tuscano JM, Jonas BA. PMID: 33777810; PMCID: PMC7991747.
      View in: PubMed   Mentions: 25  
    39. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):e611-e618. Tenold ME, Moskoff BN, Krishnan R, Rosenberg AS, Hoeg RT, Abedi M, Tuscano JM, Jonas BA. PMID: 33811007.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. Am J Hematol. 2021 04 01; 96(4):E114-E117. Jonas BA, Fisch SC, Rosenberg AS, Hoeg RT, Tuscano JM, Abedi M. PMID: 33476436.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    41. Assessing the Quality of Electronic Data for 'Fit-for-Purpose' by Utilizing Data Profiling Techniques Prior to Conducting a Survival Analysis for Adults with Acute Lymphoblastic Leukemia. AMIA Annu Symp Proc. 2020; 2020:915-924. Ngo V, Keegan TH, Jonas BA, Hogarth M, Kim KK. PMID: 33936467; PMCID: PMC8075459.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case Rep Hematol. 2020; 2020:8830123. Chang Muñoz M, Murphy JA, Wolff JE, Jonas BA. PMID: 33381331; PMCID: PMC7758129.
      View in: PubMed   Mentions: 2  
    43. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217. Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. PMID: 33119898.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    44. Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia. J Hematol. 2020 Sep; 9(3):79-83. Tuscano J, Poh C, Rosenberg A, Jonas B, Abedi M, Barisone G, Schwab E, Lundeberg K, Kaesberg P. PMID: 32855756; PMCID: PMC7430864.
      View in: PubMed   Mentions: 1  
    45. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. PMID: 32786187.
      View in: PubMed   Mentions: 815     Fields:    Translation:HumansCTClinical Trials
    46. A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):453-458. Hoeg RT, Davis J, Jonas BA, Tuscano J, Rosenberg A, Abedi M. PMID: 32171691; PMCID: PMC8530379.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    47. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia. 2019 12; 33(12):2795-2804. Jonas BA, Pollyea DA. PMID: 31628431.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    48. A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. Am J Hematol. 2019 11; 94(11):E291-E294. Tomlinson BK, Tuscano JM, Abedi M, Welborn J, Arora M, O'Donnell RT, Wun T, Jonas BA. PMID: 31379016.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    49. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2019 07; 20(7):984-997. Cortes JE, Khaled S, Martinelli G, Perl AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA, Leung AY, Mehta P, Montesinos P, Radsak M, Sica S, Arunachalam M, Holmes M, Kobayashi K, Namuyinga R, Ge N, Yver A, Zhang Y, Levis MJ. PMID: 31175001.
      View in: PubMed   Mentions: 196     Fields:    Translation:HumansCellsCTClinical Trials
    50. Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2019 08; 19(8):509-515.e1. Cortes JE, Jonas BA, Graef T, Luan Y, Stein AS. PMID: 31227358.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    51. Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. Toxics. 2019 May 09; 7(2). Malfatti MA, Buchholz BA, Enright HA, Stewart BJ, Ognibene TJ, McCartt AD, Loots GG, Zimmermann M, Scharadin TM, Cimino GD, Jonas BA, Pan CX, Bench G, Henderson PT, Turteltaub KW. PMID: 31075884; PMCID: PMC6631948.
      View in: PubMed   Mentions: 3  
    52. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. Nanomedicine. 2019 08; 20:102004. Lin TY, Zhu Y, Li Y, Zhang H, Ma AH, Long Q, Keck J, Lam KS, Pan CX, Jonas BA. PMID: 31055076; PMCID: PMC8237247.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    53. Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. Am J Hematol. 2019 07; 94(7):803-811. Medeiros BC, Chan SM, Daver NG, Jonas BA, Pollyea DA. PMID: 30945331; PMCID: PMC6593671.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    54. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core Evid. 2019; 14:3-17. Galkin M, Jonas BA. PMID: 31118877; PMCID: PMC6503332.
      View in: PubMed   Mentions: 14  
    55. Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. J Natl Cancer Inst. 2019 01 01; 111(1):78-85. Rosenberg AS, Brunson A, Jonas BA, Keegan THM, Wun T. PMID: 29897481; PMCID: PMC6335109.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    56. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019 01 03; 133(1):7-17. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. PMID: 30361262; PMCID: PMC6318429.
      View in: PubMed   Mentions: 714     Fields:    Translation:Humans
    57. Complications and early mortality in patients with acute promyelocytic leukemia treated in California. Am J Hematol. 2018 11; 93(11):E370-E372. Ho G, Li Q, Brunson A, Jonas BA, Wun T, Keegan THM. PMID: 30105792; PMCID: PMC6486372.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    58. Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. Chem Res Toxicol. 2018 10 15; 31(10):1042-1051. Scharadin TM, Malfatti MA, Haack K, Turteltaub KW, Pan CX, Henderson PT, Jonas BA. PMID: 30152692; PMCID: PMC6387632.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    59. New and emerging therapies for acute myeloid leukaemia. J Investig Med. 2018 12; 66(8):1088-1095. Davis JR, Benjamin DJ, Jonas BA. PMID: 30127098; PMCID: PMC6733983.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    60. Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio. J Investig Med High Impact Case Rep. 2018 Jan-Dec; 6:2324709618764207. Wung W, Ananthakrishnan S, Jonas BA. PMID: 29568782; PMCID: PMC5858612.
      View in: PubMed   Mentions: 1     Fields:    
    61. Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. Cancer. 2018 05 01; 124(9):1938-1945. Ho G, Wun T, Muffly L, Li Q, Brunson A, Rosenberg AS, Jonas BA, Keegan THM. PMID: 29451695; PMCID: PMC6911353.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    62. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 02; 19(2):216-228. DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. PMID: 29339097.
      View in: PubMed   Mentions: 321     Fields:    Translation:HumansCTClinical Trials
    63. Novel drug combination unleashes apoptosis in AML. Science Translational Medicine. 2018 Jan 3; 10(422):eaar7509. Jonas JB. .
      View in: Publisher Site   Mentions:
    64. Vascular endothelial cells take hematopoietic stem cells to school. Science Translational Medicine. 2017 Nov 15; 9(416):eaaq1236. Jonas JB. .
      View in: Publisher Site   Mentions:
    65. Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. Case Rep Hematol. 2017; 2017:3625946. Kjelland JD, Dwyre DM, Jonas BA. PMID: 29158926; PMCID: PMC5660754.
      View in: PubMed   Mentions: 3  
    66. Just say NO to leaky bone marrow vasculature in AML. Science Translational Medicine. 2017 Oct 4; 9(410):eaap8163. Jonas JB. .
      View in: Publisher Site   Mentions:
    67. Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer J. 2017 09 08; 7(9):e605. Rosenberg AS, Brunson A, Paulus JK, Tuscano J, Wun T, Keegan THM, Jonas BA. PMID: 28885611; PMCID: PMC5709750.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    68. On the origin of relapse in AML. Sci Transl Med. 2017 07 12; 9(398). Jonas BA. PMID: 28701479; PMCID: PMC5573257.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    69. A new therapeutic target for myelofibrosis is cause for Gli. Sci Transl Med. 2017 05 31; 9(392). Jonas BA. PMID: 28566426; PMCID: PMC5546312.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    70. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era. Br J Haematol. 2017 07; 178(1):72-80. Tao L, Clarke CA, Rosenberg AS, Advani RH, Jonas BA, Flowers CR, Keegan THM. PMID: 28542862; PMCID: PMC5487277.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    71. Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check. Sci Transl Med. 2017 04 19; 9(386). Jonas BA. PMID: 28424330; PMCID: PMC5498171.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    72. Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. Br J Haematol. 2017 06; 177(5):791-799. Ho G, Jonas BA, Li Q, Brunson A, Wun T, Keegan THM. PMID: 28419422; PMCID: PMC5444943.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    73. From MDS/AML to iPSC and back again. Sci Transl Med. 2017 03 08; 9(380). Jonas BA. PMID: 28275157; PMCID: PMC5494265.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    74. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016 11; 50:123-131. Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. PMID: 27736729.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    75. Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. Hum Pathol (N Y). 2016 Sep; 5:6-9. Su RJ, Jonas BA, Welborn J, Gregg JP, Chen M. PMID: 27458550; PMCID: PMC4957580.
      View in: PubMed   Mentions: 7  
    76. Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PLoS One. 2016; 11(7):e0159189. Jonas BA, Johnson C, Gratzinger D, Majeti R. PMID: 27428079; PMCID: PMC4948781.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    77. Individualizing Therapeutic Strategies in Acute Myeloid Leukemia: Moving Beyond the 'One-Size-Fits-All' Approach. Oncology (Williston Park). 2016 Apr; 30(4):330, 333. Jonas BA, Medeiros BC. PMID: 27085331; PMCID: PMC5495146.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    78. Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Rep Hematol. 2015; 2015:318545. Ali SF, Sonu RJ, Dwyre DM, Jonas BA, Rashidi HH. PMID: 26798525; PMCID: PMC4698528.
      View in: PubMed   Mentions: 2  
    79. Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. Cancers (Basel). 2015 Dec 14; 7(4):2459-65. Stelling A, Jonas BA, Rashidi HH, Abedi M, Chen M. PMID: 26694466; PMCID: PMC4695903.
      View in: PubMed   Mentions:
    80. B lymphoblastic leukemia with granules mimicking acute myeloid leukemia. Int J Hematol. 2015 Sep; 102(3):251-2. Song JY, Khojeini EV, Dwyre DM, Jonas BA. PMID: 26187696; PMCID: PMC5494254.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    81. Optimal Molecular Methods in Detecting p190 (BCR-ABL) Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. Case Rep Hematol. 2015; 2015:458052. Sonu RJ, Jonas BA, Dwyre DM, Gregg JP, Rashidi HH. PMID: 25949834; PMCID: PMC4407518.
      View in: PubMed   Mentions: 8  
    82. Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun. 2015; 4:15-18. McCoach CE, Rogers JG, Dwyre DM, Jonas BA. PMID: 25932381; PMCID: PMC4410270.
      View in: PubMed   Mentions: 7  
    83. MDS prognostic scoring systems – past, present, and future. Best Pract Res Clin Haematol. 2015 Mar; 28(1):3-13. Jonas BA, Greenberg PL. PMID: 25659725; PMCID: PMC4324398.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    84. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine (Lond). 2014; 9(12):1807-20. Zhang H, Li Y, Lin TY, Xiao K, Haddad AS, Henderson PT, Jonas BA, Chen M, Xiao W, Liu R, Lam KS, Pan CX. PMID: 24628688; PMCID: PMC4167557.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    85. Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation. J Biol Chem. 2011 Dec 30; 286(52):44988-99. Goodson ML, Mengeling BJ, Jonas BA, Privalsky ML. PMID: 22065574; PMCID: PMC3247966.
      View in: PubMed   Mentions: 24     Fields:    Translation:AnimalsCells
    86. Response of SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) and N-CoR (nuclear receptor corepressor) corepressors to mitogen-activated protein kinase kinase kinase cascades is determined by alternative mRNA splicing. Mol Endocrinol. 2007 Aug; 21(8):1924-39. Jonas BA, Varlakhanova N, Hayakawa F, Goodson M, Privalsky ML. PMID: 17519355; PMCID: PMC2675559.
      View in: PubMed   Mentions: 19     Fields:    Translation:AnimalsCells
    87. Corepressors: custom tailoring and alterations while you wait. Nucl Recept Signal. 2005; 3:e003. Goodson M, Jonas BA, Privalsky MA. PMID: 16604171; PMCID: PMC1402215.
      View in: PubMed   Mentions: 35     Fields:    
    88. Alternative mRNA splicing of SMRT creates functional diversity by generating corepressor isoforms with different affinities for different nuclear receptors. J Biol Chem. 2005 Mar 04; 280(9):7493-503. Goodson ML, Jonas BA, Privalsky ML. PMID: 15632172; PMCID: PMC2720035.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    89. SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathways. J Biol Chem. 2004 Dec 24; 279(52):54676-86. Jonas BA, Privalsky ML. PMID: 15491994; PMCID: PMC2653424.
      View in: PubMed   Mentions: 41     Fields:    Translation:Cells
    Brian's Networks
    Concepts (274)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (39)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UC Davis Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-5-g94c7c43e on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California